Scholarlink

Abstract <p>Despite recent therapeutic advances, renal cell carcinoma (RCC) has a high mortality rate. The development of new neoadjuvant strategies requires reliable companion biomarkers of early and successful response to treatment. A change in tumor size is a late measure of response and novel targeted imaging-based biomarkers may be more accurate for treatment response prediction. Here we evaluated the potential of hyperpolarized carbon-13 MRI (HP <sup>13</sup>C-MRI), following the injection of hyperpolarized <sup>13</sup>C-pyruvate, to assess response to neoadjuvant treatment in four patients with clear cell RCC as an exploratory outcome within a prospective clinical trial. The change in the tumor lactate-to-pyruvate ratio (LAC/PYR) following treatment varied across the patients: mean percentage change ± S.D. = +6 ± 27%. The largest decrease in LAC/PYR ratio was in the patient treated with cediranib monotherapy (-21%), followed by a smaller reduction in a patient receiving the combination of cediranib and olaparib (-14%). An increase in the LAC/PYR ratio post-treatment was observed in the second patient receiving combination treatment (+ 21%), with the largest increase in the patient receiving olaparib monotherapy (+ 35%). Metabolic changes were observed following treatment in the absence of significant changes in tumor size. In summary, HP <sup>13</sup>C-MRI successfully captured heterogeneous metabolic responses to cediranib and olaparib therapy, revealing both increases and decreases in tumor lactate labelling, independent of any morphologic change. Finally, this is the first study to evaluate the potential of clinical HP <sup>13</sup>C-MRI to assess early treatment response in renal cancer by using a range of therapeutics.</p> Key take home message <p>The study provides preliminary evidence supporting HP <sup>13</sup>C-MRI as a promising imaging biomarker for evaluating early metabolic changes in renal cell carcinoma following neoadjuvant therapy. </p> Clinical Trials&#xa0;Registry <p>NCT03741426,&#xa0;Registration date: 13 November 2018.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Ines Horvat-Menih,
  • Mary A McLean,
  • Jonathan Birchall,
  • Maria Jesus Zamora Morales,
  • Marta Wylot,
  • Stephan Ursprung,
  • Ramona Woitek,
  • Eva Serrao,
  • Ashley Grimmer,
  • Elizabeth Latimer,
  • Alixander S Khan,
  • Andrew N Priest,
  • Andrew B Gill,
  • Joshua D Kaggie,
  • Martin J Graves,
  • Tristan Barrett,
  • James MS Wason,
  • Helen Mossop,
  • Martin Thomas,
  • Sulekha Said,
  • Anne Y Warren,
  • Kate Fife,
  • Tim Eisen,
  • Athena Matakidou,
  • Will Ince,
  • Brent O’Carrigan,
  • James O Jones,
  • Sarah J Welsh,
  • Thomas J Mitchell,
  • James N Armitage,
  • Antony CP Riddick,
  • Grant D Stewart,
  • Ferdia A Gallagher

摘要

Abstract

Despite recent therapeutic advances, renal cell carcinoma (RCC) has a high mortality rate. The development of new neoadjuvant strategies requires reliable companion biomarkers of early and successful response to treatment. A change in tumor size is a late measure of response and novel targeted imaging-based biomarkers may be more accurate for treatment response prediction. Here we evaluated the potential of hyperpolarized carbon-13 MRI (HP 13C-MRI), following the injection of hyperpolarized 13C-pyruvate, to assess response to neoadjuvant treatment in four patients with clear cell RCC as an exploratory outcome within a prospective clinical trial. The change in the tumor lactate-to-pyruvate ratio (LAC/PYR) following treatment varied across the patients: mean percentage change ± S.D. = +6 ± 27%. The largest decrease in LAC/PYR ratio was in the patient treated with cediranib monotherapy (-21%), followed by a smaller reduction in a patient receiving the combination of cediranib and olaparib (-14%). An increase in the LAC/PYR ratio post-treatment was observed in the second patient receiving combination treatment (+ 21%), with the largest increase in the patient receiving olaparib monotherapy (+ 35%). Metabolic changes were observed following treatment in the absence of significant changes in tumor size. In summary, HP 13C-MRI successfully captured heterogeneous metabolic responses to cediranib and olaparib therapy, revealing both increases and decreases in tumor lactate labelling, independent of any morphologic change. Finally, this is the first study to evaluate the potential of clinical HP 13C-MRI to assess early treatment response in renal cancer by using a range of therapeutics.

Key take home message

The study provides preliminary evidence supporting HP 13C-MRI as a promising imaging biomarker for evaluating early metabolic changes in renal cell carcinoma following neoadjuvant therapy.

Clinical Trials Registry

NCT03741426, Registration date: 13 November 2018.